iCAD also recognizes the importance of 3D tomosynthesis to the diagnosis of breast cancer. This technology provides radiologists with an unprecedented amount of data to aid in their diagnosis. In order to efficiently utilize this amount of information, radiologists need additional tools to streamline their workflow. iCAD is working closely with several of its OEM partners to design and develop a robust CAD solution specifically for tomosynthesis that will optimize workflow for the radiologists by making it easier to detect regions of interest. At RSNA 2013, iCAD will display its latest version of this technology as a “works in progress.”In addition to a presence in the Invivo Corporation’s booth (#2700 in South Building, Hall A), DynaCAD, iCAD’s MRI product suite for quantification image analysis of the breast, prostate and other organs, will also be featured in a Scientific Formal Presentation taking place on Friday, December 6 from 10:30 a.m. to 12:00 p.m. in Room N230 in the North Building. The session will discuss “Tumor Cellularity and the Extravascular-Extracellular Space: Using Quantitative Imaging to Evaluate Correlation Between ADC and DCE MRI in Human Gliomas, Meningiomas and Cerebral Lymphomas,” a study co-authored by Naira Muradyan, PhD, Lead Senior Research Scientist, iCAD, Inc., which may provide new imaging biomarkers of brain tumor cellularity. For additional information regarding iCAD and the technologies on display at RSNA 2013, please visit http://www.icadmed.com/newsevents/rsna2013.htm. About the Radiological Society of North America (RSNA)RSNA is an association of more than 53,000 radiologists, radiation oncologists, medical physicists and related scientists, promoting excellence in patient care and health care delivery through education, research and technologic innovation. The Society is based in Oak Brook, Ill. (RSNA.org) About iCAD, Inc.iCAD is an industry-leading provider of Computer-Aided Detection (CAD) technologies, advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of common cancers. iCAD offers a comprehensive range of high-performance, upgradeable CAD solutions for mammography and advanced image analysis and workflow solutions for Magnetic Resonance Imaging, for breast and prostate cancers and Computed Tomography for colorectal cancer. iCAD’s Xoft System, offers radiation treatment for early-stage breast cancer that can be administered in the form of Intraoperative Radiation Therapy or accelerated partial breast irradiation. The Xoft System is also cleared for the treatment of non-melanoma skin cancer and gynecological cancers. For more information, call (877) iCADnow, or visit www.icadmed.com. "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the Company’s ability to defend itself in litigation matters, the Company’s ability to identify a replacement for the Axxent FlexiShield Mini, the risks relating to the Company’s acquisition of Xoft including, the expected benefits of the acquisition may not be achieved in a timely manner, or at all; the Xoft business operations may not be successfully integrated with iCAD’s and iCAD may be unable to achieve the expected synergies, business and strategic objectives following the transaction, the risks of uncertainty of patent protection; the impact of supply and manufacturing constraints or difficulties; product market acceptance; possible technological obsolescence; increased competition; customer concentration; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “anticipate”, “likely”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov .